Physician profile
John C Steele
NPI 1942350616
$9,247.76
in general payments reported to CMS, 2019-2025
26 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $821 · 2021: $1,117 · 2022: $1,465 · 2023: $1,812 · 2024: $1,589 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,359.55 | 2019-2024 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,236.85 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Neurocrine Biosciences, INC. | $1,234.63 | 2020-2025 | Ingrezza |
| Abbvie INC. | $925.37 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $771.77 | 2020-2025 | Caplyta |
| Alkermes, INC. | $763.35 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $416.63 | 2019-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $365.37 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $330.82 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Bausch Health US, LLC | $296.54 | 2020-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $288.06 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $247.61 | 2019-2022 | |
| Eisai INC. | $225.02 | 2020-2021 | |
| Almatica Pharma LLC | $181.90 | 2023-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $178.56 | 2020-2023 | Belsomra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $110.48 | 2019-2021 | |
| Axsome Therapeutics, INC. | $54.58 | 2024 | Auvelity |
| Allergan, INC. | $54.42 | 2020 | |
| Indivior INC. | $50.45 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $38.45 | 2019 | |
| Noven Therapeutics, LLC | $31.00 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $22.72 | 2025 | Quviviq |
| Supernus Pharmaceuticals, INC. | $21.31 | 2025 | Qelbree |
| Tris Pharma INC | $17.41 | 2023 | Dyanavel Xr |
| Aytu Biopharma, INC. | $14.13 | 2021 | |
| Corium, LLC | $10.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.